Board of Directors

Brian M. Culley, M.A., M.B.A. — Chief Executive Officer, Director

Mr. Culley has more than 20 years of experience in the life science industry. He has served as our chief executive officer since February 2010 and as a member of our board of directors since December 2011. Previously, from January 2007 to February 2010, he served as our chief business officer and senior vice president, from February 2006 to January 2007, he served as our senior vice president, business development, and, from December 2004 to February 2006, he served as our vice president, business development. From 2002 until 2004, Mr. Culley managed all strategic collaborations and licensing agreements for Immusol, Inc. in San Diego, where his most recent title was director of business development and marketing. From 1999 until 2000, he was a licensing and marketing associate at the University of California, San Diego, department of technology transfer & intellectual property services and from 1996 to 1999, he was a research associate for Neurocrine Biosciences, Inc. He received a B.S. in biology from Boston College, a masters in biochemistry from the University of California, Santa Barbara and an M.B.A. from The Johnson School of Business at Cornell University.

Howard C. Dittrich, M.D. — Director

Chair — Compensation Committee
Chair — Nominating and Governance Committee

Dr. Dittrich has served on our Board of Directors since June 2014. A cardiologist with more than 20 years of experience in cardiac therapeutic research and clinical development, Dr. Dittrich joined Frazier Healthcare Partners in January 2016 as an Entrepreneur-in-Residence and also began serving as Chief Medical Officer of Hawkeye Therapeutics, a biotechnology company formed by Frazier. In addition, he currently serves as President and a member of the board of directors of Advanced Endovascular Therapeutics, Inc., a privately-held biotechnology company that he co-founded in August 2015, and since December 2015, he has served as consulting Chief Medical Officer of Leading Biosciences, Inc., a privately-held, clinical-stage pharmaceutical company. Additionally, Dr. Dittrich co-founded and serves as Chairman of the board of directors of IOWA Approach Inc., a privately-held company developing atrial fibrillation ablation technology. He also is an Adjunct Professor of Medicine at the University of Iowa Carver College of Medicine and serves as Chair of the board of directors of the François M. Abboud Cardiovascular Research Center at the University of Iowa Carver College of Medicine. From November 2011 to November 2015, Dr. Dittrich served as Chief Medical Officer of Laguna Pharmaceuticals, a privately-held biopharmaceutical company. From April 2012 to July 2014, he served as Chief Medical Officer of Sorbent Therapeutics, a privately-held biopharmaceutical company. Previously, from June 2003 until it was acquired by Merck & Co., Inc. in September 2007, Dr. Dittrich served as Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs of NovaCardia, Inc., a clinical-stage pharmaceutical company focused on cardiovascular diseases, and, from September 2007 to June 2011, he co-founded and served as Chief Medical Officer of Sequel Pharmaceuticals, Inc., a privately-held pharmaceutical company spun out from NovaCardia following its acquisition by Merck. Prior to NovaCardia, from 1996 to 2002, Dr. Dittrich held executive positions overseeing clinical development and regulatory affairs at Molecular Biosystems, Inc. and Alliance Pharmaceutical Corp., during which time he was instrumental in gaining U.S. Food and Drug Administration approval of two cardiovascular imaging agents. From 1984 to 1996, he was a full-time faculty member of the Department of Medicine at the University of California, San Diego (UCSD) and, from 1996 to 2011, he served part-time as Clinical Professor of Medicine at UCSD. Dr. Dittrich holds a B.S. degree from the University of Iowa and an M.D. from the University of Iowa Carver College of Medicine. He completed his residency in internal medicine and clinical fellowship in cardiology at UCSD.

Peter Greenleaf — Director

Member — Audit and Compensation Committees

Mr. Greenleaf has served on our board of directors since November 2015. Mr. Greenleaf currently serves as Chief Executive Officer and member of the Board of Directors of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), which is focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide. Prior to joining Sucampo, Mr. Greenleaf served as Chief Executive Officer and member of the Board of Directors of Histogenics Corporation, a regenerative medicine company. Prior to Histogenics, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca from 2006 to 2013, where he most recently served as President and where he was instrumental in the sale of MedImmune to AstraZeneca for approximately $15.6 billion in 2007. While at MedImmune, Mr. Greenleaf drove the expansion of MedImmune’s pipeline into over 120 clinical and pre-clinical programs and the commercialization of its marketed products. Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) and Boehringer Mannheim G.m.b.H. (now Roche Holdings). Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf is also a member of the Board of Directors of the Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies and Health Sections. Mr. Greenleaf earned a M.B.A degree from St. Joseph’s University and a B.S. degree from Western Connecticut State University.

Matthew Pauls — Chair of the Board

Chair — Compensation, Audit, and Nominating & Governance Committees

Matthew Pauls has served on our board of directors since October 2015 and is the chair of our board. Mr. Pauls brings more than 20 years of experience in the pharmaceutical industry, including senior leadership roles in a broad spectrum of operational areas and significant experience in new product launches, commercial and technical operations, as well as clinical development, with a specific focus on orphan drug candidates. Mr. Pauls currently serves as President and Chief Executive Officer and on the Board of Directors of Strongbridge Biopharma plc (NASDAQ: SBBP), a biopharmaceutical company focused on therapies that target rare diseases. Prior to joining Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a global biopharmaceutical company focused on rare diseases. Prior to Insmed, Mr. Pauls served as Senior Vice President, Head of Global Commercial Operations at Shire Pharmaceuticals, a global specialty biopharmaceutical company. Earlier in his career, Mr. Pauls also held senior positions at Bristol-Myers Squibb in Brand Management and Payor Marketing, and at Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.

David A. Ramsay — Director

Chair — Audit Committee
Member — Nominating & Governance Committee

Mr. Ramsay has served on our Board of Directors since June 2011. Mr. Ramsay retired from Halozyme Therapeutics, Inc. (NASDAQ: HALO) in July 2015, where he served as Chief Financial Officer since May 2013 and from 2003 to May 2009. He also served as Halozyme’s Vice President, Corporate Development from May 2009 to May 2013. From 2000 to 2003, Mr. Ramsay was Vice President, Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life science industry. From 1998 to 2000, he was with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), where he served as Vice President, Treasurer and Director, Corporate Finance. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and a M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.